Johnson & Johnson (J&J) announced Tuesday that it would acquire Massachusetts-based Abiomed, gaining access to the medical device company’s Impella heart pump, which treats conditions such as heart attack, heart failure and clogged arteries. J&J will pay $380 per share upfront in cash, which equates to a value of approximately $16.6 billion.